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 Abstract
Background: Embryonal rhabdomyosarcoma in a form of a polyp of the uterine cervix occurs mainly in young 
women in their second decade of life. The characteristic microscopic features are: the submucosal cambium layer 
and the presence of rhabdomyoblasts in the stroma. So far the treatment has not been well defined and ranges 
from conservative to radical surgery.          
Case: The presented case is a 22-year old woman with cervical polyp. Polypectomy with D&C was performed in 
2005 and the microscopic examination revealed rhabdomyosarcoma botryoides. Detailed examination diagnosed 
stage Ia of the disease. The patient received 6 cycles of chemotherapy (Vincristine and Actinomycin).       
Conclusion: Conservative treatment may be considered in young women with favorable prognostic factors who 
wish to preserve their fertility. Polypectomy followed by chemotherapy is a possible option for such patients.  
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Background  
Rhabdomyosarcoma	is	a	soft	tissue	tumor,	localized	in	20%	
in	 the	genitourinary	 tract.	 In	more	 than	50%	of	cases	 it	occurs	
as	 embryonal	 subtype.	 Being	 a	 tumor	 of	 skeletal	muscle,	 it	 is	
classified	as	heterologous	sarcoma	of	the	female	genital	tract	[1].	
The	Intergroup	Rhabdomyosarcoma	Study	(IRS)	Group	identified	
3	major	histologic	subtypes	of	 rhabdomyosarcoma:	embryonal,	
alveolar	and	undifferentiated	[2].	Sarcoma	botryoides	is	a	form	
of	embryonal	rhabdomyosarcoma	with	characteristic	grape-like	
appearance.	
Embryonal	 rhabdomyosarcoma	 arises	 from	 unsegmented	
and	undifferentiated	mesoderm.	Microscopically,	the	tumor	cells	
are	 small	 and	 spindle	 shaped.	 Some	have	 a	 deeply	 acidophilic	
cytoplasm.	A	feature	of	diagnostic	value	is	the	presence	of	highly	
cellular	areas,	usually	surrounding	blood	vessels,	alternating	with	
parvicellular	 regions	 that	 have	 abundant	 mucoid	 intercellular	
material.	A	highly	characteristic	feature	of	the	polypoid	(botryoid)	
tumors	is	the	presence	of	a	dense	zone	of	undifferentiated	tumor	
cells,	 directly	 beneath	 the	 epithelium,	 the	 formation	 known	 as	
Nicholson’s	 cambium	 layer.	 Cross	 striations	 may	 or	 may	 not	
be	present	[3].	A	prognostically	favorable	variant	of	embryonal	
rhabdomyosarcoma	is	represented	by	the	spindle	cell	type.		
In	a	 female	 infant,	 in	 the	genitourinary	 tract,	vagina	 is	 the	
most	common	location.	Cervical	embryonal	rhabdomyosarcoma	
is	a	rare	entity	and	is	seen	in	young	women	mainly	in	the	second	
and	 	 the	 third	 decade	 of	 their	 life,	macroscopically	 having	 an	
appearance	of	polypoid	structures.	Microscopically,	both	vaginal	
and	 cervical	 lesions	 share	 similar	 characteristic	 pathologic	
features:	 a	 submucosal	 cambium	 layer	 and	 the	 presence	 of	
rhabdomyoblasts	in	the	stroma	[1].				
Case report
A	22-	year	old	woman,	gravida	0,	was	referred	to	The	Maria	
Sklodowska	 Curie	 Memorial	 Cancer	 Center,	 Department	 of	
Gynecological	Oncology	in	October	2005.	One	month	earlier	the	
cervical	polyp	had	been	discovered	during	routine	gynecological	
examination	and	polypectomy	with	 fractional	curettage	 (D&C)	
was	performed.
 Streszczenie
Mięsak groniasty może występować w postaci polipa szyjki macicy, głównie u młodych kobiet w drugiej dekadzie 
życia. Na charakterystyczny obraz mikroskopowy składają się zagęszczenia niezróżnicowanych komórek w warstwie 
podśluzówkowej i obecność rhabdomyoblastów w podścielisku. Leczenie chirurgiczne nie zostało jednoznacznie 
określone i mieści się w szerokim zakresie od chirurgii oszczędzającej do radykalnej.          
Opis przypadku: Prezentowany przypadek dotyczy 22 letniej kobiety z polipem szyjki macicy. W 2005 roku 
wykonano usunięcie polipa oraz wyłyżeczkowanie kanału szyjki i jamy macicy a badanie mikroskopowe materiału 
wykazało mięsaka groniastego. Po dokładnej diagnostyce ustalono stopień zaawansowania nowotworu Ia. 
Pacjentka otrzymała 6 cykli chemioterapii wg schematu (VA)       
Wnioski: U młodych kobiet pragnących zachować płodność, z korzystnymi czynnikami rokowniczymi można 
rozważyć leczenie oszczędzające. Jedną z możliwych opcji jest usunięcie polipa z uzupełniającą chemioterapią.   
 Słowa kluczowe: mięsak groniasty / polip szyjki macicy / leczenie oszczędzające / 
     /  chemioterapia / 
 
Figure 1. Small spindle cells with acidophilic cytoplasm (200x).
 
Figure 2. Characteristic feature of highly cellular area surrounding blood vessel 
(in the center of picture) alternating with parvicellular regions that have abundant 
mucoid intracellular material (left side of picture). 
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The	microscopic	examination	revealed	rhabdomyosarcoma	
botryoides.	 Immunohistochemical	 analysis	 were	 as	 follows:	
desmin	 (+/-),	actin	 (-),	MIB-1	 (+++),	vimentin	 (+),	cytokeratin	
(-).
Microscopically,	picture	composed	of	small	spindle	cells	with	
acidophilic	cytoplasm	was	present	with	a	characteristic	feature	of	
highly	cellular	area	surrounding	a	blood	vessel		alternating	with	
parvicellular	 regions	 that	 have	 abundant	 mucoid	 intracellular	
material.	(Figure	1	and	Figure	2).	
The	 patient	 underwent	 a	 thorough	 clinical	 examination,	
chest	X-ray,	 abdominal	 and	 transvaginal	 ultrasound	 and	pelvic	
MRI.	The	results	showed	no	evidence	of	metastatic	or	residual	
disease.	
Diagnostic	hysteroscopy	was	performed	on	the	10th	day	of	
the	cycle	and	showed	normal	cervical	canal	and	uterine	cavity.	
According	 to	 the	 Intergroup	 Rhabdomyosarcoma	 Study	 (IRS)	
criteria,	it	was	classified	as	group	IA	(4).	
The	 patient	 was	 subsequently	 scheduled	 for	 adjuvant	
chemotherapy	 with	 Vincristine,	 1,5mg/m2	 	 the	 first	 day,	 at	
a	 maximum	 dose	 of	 2mg	 and	 Dactinomycin	 at	 a	 dose	 of	 
0,015mg/kg	from	the	first	until	the	fifth	day,	at	a	maximum	dose	
of	0,5mg/day.	Chemotherapy	was	given	in	4-week	intervals	for	6	
cycles	with	good	tolerance	without	any	significant	toxicity.	The	
menstrual	periods	were	painful,	but	 regular.	The	gynecological	
examination	 and	 transvaginal	 ultrasound	were	 performed	 after	
the	3rd	 and	 the	6th	 cycle	of	 chemotherapy.	The	 treatment	was	
completed	without	delays	in	April	2006.
Table I. The review of patients treated by polypectomy.  
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In	June	2006,		the	transvaginal	ultrasound		showed	normal	
uterus	 and	 ovaries	 without	 any	 abnormalities.	 Hysteroscopy	
showed	 normal	 uterine	 cavity	 and	 cervical	 canal	 without	 any	
pathologic	 findings,	 endometrial	 and	 endocervical	 random	
biopsies	 were	 negative.	 The	 patient	 became	 pregnant	 and	
delivered	 on	 February	 15,	 2009.	 The	 patient	 remains	 without	
evidence	of	disease	71	months	following	the	initial	diagnosis	of	
botryoid	sarcoma.	
Discussion 
Sarcoma	botryoides	in	a	form	of	a	polyp	of	the	uterine	cervix	
is	a	rare	entity	and	may	occur	in	young	women	and	adolescents.		
In	1987	Brand	et	al.,	reported	4	cases	of	sarcoma	botryoides	
of	the	uterine	cervix	and	presented	the	review	of	literature	with	
other	17	 cases,	which	 resulted	 in	 the	 total	 number	of	21	 cases	
reported	 until	 1987	 [5].	 In	 that	 review,	 treatment	 ranged	 from	
polypectomy	(2	patients)	to	radical	surgery	and	exenteration	with	
additional	radio-	and/or	chemotherapy.	One	of	 the	 two	patients	
after	 polypectomy	 survived	 16	 months	 without	 any	 additional	
treatment	[5].	
Radical	 surgery	was	 traditionally	 the	method	 of	 choice	 in	
the	 treatment	of	 sarcoma	botryoides.	 In	 the	1970s	 the	standard	
management	consisted	of	pelvic	exenteration	which	enabled	the	
recovery	of	about	50%	of	patients.	By	mid	1970s	it	was	documented	
that	pelvic	exenteration	may	be	abandoned	and	replaced	by	a	less	
mutilating	surgery	and	combined	with	chemotherapy.
Moreover,	the	majority	of	the	patients	with	cervical	lesions	
are	 young	 and	 therefore	 the	 possibility	 of	 fertility	 sparing	
treatment	should	be	considered.	
In	 1988	 Daya	 and	 Scully	 reported	 13	 cases	 of	 sarcoma	
botryoides	in	cervical	polyps,	thus	comprising	the	largest	series	
to	 date	 of	 original	 cases	 [6].	 Five	 patients	 were	 treated	 with	
conservative	 surgery:	 1	 with	 cervicectomy,	 3	 patients	 with	
polypectomy	 and	 1	 with	 polypectomy	 and	 chemotherapy.	All	
survived	from	1	to	8	years	and	that	study	proved	the	prognosis	
was	similar	in	cases	treated	conservatively	and	in	a	more	radical	
manner.		
Polypoid	 form	 of	 rhabdomyosarcoma	 has	 been	 suggested	
to	 have	 a	 more	 favorable	 prognosis.	 However,	 the	 potential	
invasiveness	should	be	kept	 in	mind	 	as	1	patient	 in	Daya	and	
Scully		series	presented	recurrent	polyps	and	eventually	died	of	
the	disease	despite	radical	surgery	and	subsequent	chemotherapy	
[6].	
The	 case	 report	 published	 by	 Bernal	 et	 al.,	 concerned	 a	
19-year-old	 patient	 with	 a	 cervical	 polyp	 [7].	 Endocervical	
curettage	 and	 evacuation	 of	 the	 polyp	 were	 performed	 and	
cervical	 conization	 was	 also	 decided	 due	 to	 the	 pathologic	
evaluation	 revealing	 embryonal	 rhabdomyosarcoma	 in	 both	
samples.	Even	though	no	residual	tumor	was	present	in	cervical	
specimen,	she	was	scheduled	for	chemotherapy	and	received	6	
cycles	of	Vincristine	and	Dactinomycin	[7].	
Zanetta	 et	 al.,	 reported	 3	 cases	 of	 rhabdomyosarcoma	 in	
cervical	 polyps	 in	 young	 women	 treated	 conservatively	 with	
polypectomy	 and	 local	 excision,	 followed	 by	 chemotherapy	
(Doxorubicin,	Ifosfamide).	In	all	 three	cases	the	follow	up	was	
up	to	36	months.	Local	recurrence	occurred	in	1	patient	after	9	
months	 and	 was	 treated	 by	 loop	 excision.	 The	 two	 remaining	
patients	were	free	of	disease	[8].				
The	 appropriate	 therapy	 for	 sarcoma	 botryoides	 arising	 in	
the	cervix	has	not	been	well-defined	as	it	is	a	rare	tumor	and	data	
are	based	on	individual	case	reports.	The	majority	of	the	patients	
are	young,	 in	 their	 second	decade	of	 life,	 and	 in	an	attempt	 to	
maximize	the	reproductive	potential	a	conservative	surgery	with	
preservation	of	fertility	should	be	considered.
Since	 the	 report	 published	 in	 1987	 by	 Brand	 and	 al.,	 the	
review	 of	 the	 literature	 has	 shown	 very	 limited	 number	 of	
cases	 with	 location	 in	 polyps	 treated	 conservatively	 with	 or	
without	 additional	 chemotherapy	 [9,10,11,12,13].	The	 cases	 of	
polypectomy,	including	current	study,	are	presented	in	table	I.
Among	 13	 patients,	 local	 recurrence	 occurred	 in	 1	
patient	 despite	 	 chemotherapy,	 1	 patient	 died	 (not	 treated	with	
chemotherapy).The	 remaining	 11	 patients	 survived	 without	
recurrence,	regardless	of	receiving	or	not	chemotherapy	.
Sarcoma	 botryoides	 is	 a	 highly	 malignant	 subgroup	 of	
rhabdomyosarcoma	 (RMS),	 but	 fortunately	 in	 most	 cases	 it	
is	 responsive	 to	 chemotherapy	 and	 radiation.	Due	 to	 its	 rarity,	
Table II. The possible modifications of chemotherapy regimens.  
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the	 best	 choice	 of	 adjuvant	 treatment,	 especially	 at	 the	 early	
stages	of	the	disease,	is	still	a	matter	of	controversy	and	requires	
further	investigation.	Nowadays	surgery	followed	by	an	adjuvant	
multidrug	 chemotherapy	 is	 the	 most	 frequent	 therapeutic	
option	 [14].	 Radiation	 is	 actually	 indicated	 in	 patients	 with	
persistent	or	recurrent	disease	[15].	The	employment	of	effective	
antineoplastic	 agents	 in	 adjuvant	 settings	 encourages	 a	 more	
conservative	surgical	approach.	Because	sarcoma	botryoides	of	
the	cervix	usually	occurs	as	a	localized	disease	it	is	possible	not	
only	to	cure	but	also	to	preserve	the	fertility	of	patients	[11,	12,	
14].	Undoubtedly,	multiagent	treatment	consisting	of	Vincristine,	
Dactinomycin	and	Cyclophosphamide	(VAC)	is	the	most	popular	
adjuvant	chemotherapy	regimen	in	adolescents	and	young	adult	
patients	 with	 cervical	 sarcoma	 botryoides.	 The	 recommended	
regimens	and	dosage	may	vary	and	are	shown	in	table	II.	
The	number	of	given	cycles	ranges	from	three	to	twelve	[10,	
13,	16].	Totally	excised	tumors	of	embryonal	histology	localized	
in	 the	 female	 genital	 tract	 have	 an	 excellent	 prognosis	 when	
treated	with	 adjuvant	multiagent	 chemotherapy,	much	 superior	
than	other	subgroups	of	rhabdomyosarcomas	[17].	Therefore,	in	
patients	with	group	 I	embryonal	RMS,	 the	“low-risk”	patients,	
less	aggressive	schedule	is	usually	chosen	with	fairly	satisfactory	
results.	 It	 consists	 of	 Vincristine	 and	 Dactinomycin	 (VA)	 [7,	
18,	 19].	 The	 aim	 of	 this	 regimen	 is	 to	 avoid	 disturbances	 in	
the	 endocrine	 system	 of	 young	 patients	 as	 much	 as	 possible.	
Cyclophosphamide	 is	 one	 of	 the	 cytostatics	 which	 inhibit	
hormonal	ovarian	function	more	frequently.	
Ifosfamide	 belongs	 to	 the	most	 active	 drugs	 in	 sarcomas.	
There	 are	 only	 few	 published	 cases	 of	 treating	 young	women	
with	sarcoma	botryoides	with	chemotherapy	based	on	Ifosfamide	
and	Doxorubicin	[8].	Regimens	containing	more	cytostatics,	as	
Ifosfamide,	 Dactinomycin	 and	 Vincristine	 (IVA),	 sometimes	
sequentially	 with	 Doxorubicin	 and	 Cisplatin	 or	 multidrug	
chemotherapy	 VAIA	 (Ifosfamide,	 Dactinomycin,	 Doxorubicin	
and	 Vincristine),	 widely	 used	 in	 “high-risk”	 children	 patients,	
have	no	 role	 in	 the	 treatment	of	older	patients	 [20,	21,	22,	23,	
24].	
As	a	result	of	the	IRS	study	group,	VA	has	been	concluded	to	
appear	as	effective	as	VAC	in	the	group	I	disease	and	possibly	to	
spare	the	adolescents	complete	alopecia	and	reduce	toxicity	[2].	
Between	6	and	12	cycles	are	recommended	in	the	literature.
Conclusion	
Surgical	procedures,	even	at	early	stages	of	the	disease,	range	
from	polypectomy,	 cervicectomy	 (trachelectomy)	 up	 to	 radical	
hysterectomy.	In	young	women	wishing	to	preserve	their	fertility,	
the	conservative	treatment	–	polypectomy	–	may	be	considered	as	
the	results	are	similar	to	those	of	a	more	radical	surgery.
Moreover,	it	seems	that	the	extent	of	the	disease	is	the	most	
important	prognostic	factor.
Consequently,	 patients	 with	 favorable	 prognostic	 factors	
(disease	 classified	 as	 clinical	 group	 I	 with	 localized	 lesion,	
without	a	deep	myometrial	invasion,	in	the	form	of	a	single	polyp	
and	with	embryonal	histology),	may	be	treated	successfully	with	
conservative	surgery.		
In	fact,	there	is	no	evidence	that	chemotherapy	is	necessary	
at	an	early	stage	Ia	of	sarcoma	botryoides	after	surgical	excision.	
However,	 the	 prognosis	 which	 had	 been	 very	 bad	 before	
introduction	of	chemotherapy,	has	now	improved	so	it	may	be	an	
argument	in	favor	of	the	adjuvant	treatment.
The	thorough	evaluation	of	the	extend	of	the	disease	should	
be	performed,	using	imaging	techniques	(ultrasonography/MRI)	
and	hysteroscopy	with	biopsy	of	the	suspicious	area.	
The	 close	 follow-up	 is	 highly	 recommended	 as	 the	 risk	
of	 relapse	 is	 not	 negligible,	 and	 early	 detection	 is	 crucial	 for	
subsequent	effective	therapy.			
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